SNSE News and Press, Sensei Biotherapeutics Inc. From 05/09/24

2024-05-09 11:09:34 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics Read the full article on Seeking Alpha ...

- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion...

2024-05-03 08:29:21 ET More on premarkets gainers & stock Zura Bio stock jumps on plans to raise $112.5M in private financing Financial information for Binah Capital Group, Inc. Financial information for Healthcare Triangle Seeking Alpha’s Quant Ra...

A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...

2024-05-02 12:49:49 ET Gainers: Emergent Biosolutions EBS +96% . XBP Europe Holdings ( XBP ) +56% . Aspen Aerogels ASPN +52% . Syra Health Corp ( SYRA ) +47% . Safe & Green Holdings Corp SGBX +42% . Sensei Biotherapeutics ( SNSE ...

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combin...

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nat...

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled...

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its cond...

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escal...